Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18326031 
Maitra S, et al. (2008) The AU-rich element mRNA decay-promoting activity of BRF1 is regulated by mitogen-activated protein kinase-activated protein kinase 2. RNA 14, 950-9 18326031
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download Sites

S54-p - BRF1 (human)
Orthologous residues
BRF1 (human): S54‑p, BRF1 (mouse): S54‑p, BRF1 (rat): S54‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  fibrosarcoma, fibrosarcoma of soft tissue
 Relevant cell lines - cell types - tissues:  HT1080 (fibroblast), SlowC (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE MAPKAPK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MAPKAPK2 (human) pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anisomycin increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  transcription, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
14-3-3 beta (human) Induces co-immunoprecipitation
 Comments:  inhibits BRF1-dependent AMD ( ARE-mediated mRNA decay)

S92-p - BRF1 (human)
Orthologous residues
BRF1 (human): S92‑p, BRF1 (mouse): S92‑p, BRF1 (rat): S92‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  fibrosarcoma, fibrosarcoma of soft tissue
 Relevant cell lines - cell types - tissues:  HT1080 (fibroblast), SlowC (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE MAPKAPK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MAPKAPK2 (human) pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anisomycin increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  transcription, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
14-3-3 beta (human) Induces co-immunoprecipitation
 Comments:  inhibits BRF1-dependent AMD ( ARE-mediated mRNA decay)

S203-p - BRF1 (human)
Orthologous residues
BRF1 (human): S203‑p, BRF1 (mouse): S203‑p, BRF1 (rat): S203‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  fibrosarcoma, fibrosarcoma of soft tissue
 Relevant cell lines - cell types - tissues:  HT1080 (fibroblast), SlowC (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE MAPKAPK2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE MAPKAPK2 (human) pharmacological activator of upstream enzyme, transfection of constitutively active enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
anisomycin increase
Downstream Regulation
 Effect of modification (function):  molecular association, regulation
 Effect of modification (process):  transcription, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
14-3-3 beta (human) Induces co-immunoprecipitation
 Comments:  inhibits BRF1-dependent AMD ( ARE-mediated mRNA decay)


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.